Myriad Genetics. has been granted a patent for a computer-implemented method that infers genetic ancestry from low-coverage genomic data. The method involves generating a reference matrix, decomposing it, and deriving ancestral attribution vectors to determine a patient’s genetic ancestry based on their genetic data. GlobalData’s report on Myriad Genetics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Myriad Genetics, Personalized medicine biomarkers was a key innovation area identified from patents. Myriad Genetics's grant share as of June 2024 was 29%. Grant share is based on the ratio of number of grants to total number of patents.
Genetic ancestry inference from low-coverage genomic data
The patent US12033722B2 outlines a method for genetic screening that utilizes advanced computational techniques to analyze a patient's genetic data. The process begins with deriving genetic data, including raw sequencing data and genetic markers, from a patient's genome. A computing device identifies a genetic reference dataset that includes dosage information for various subjects at specific loci. This dataset is then transformed into a reference matrix, which serves as a foundation for generating an ancestral attribution matrix. This matrix attributes genetic descent from proposed ancestral populations to the subjects, allowing for the creation of simulated ancestral attribution vectors stored in a K-dimensional tree. The method ultimately derives ancestral attribution vectors for the patient, which reflect the admixture of populations contributing to the patient's genetic ancestry.
Additionally, the patent details various enhancements to the genetic screening method, such as the use of low-coverage next-generation sequencing and high-throughput sequencing procedures. It addresses the imputation of missing dosage data and the generation of probabilistic dosage values within the reference matrix. The method also includes constraints to ensure that the proportions of descent from ancestral populations are accurately represented. Furthermore, it describes the iterative merging of reference clusters and the definition of dines that connect these clusters, which aids in determining the patient's genetic ancestry. Overall, the patent presents a comprehensive approach to genetic screening that leverages computational power to enhance the understanding of genetic ancestry and population admixture.
To know more about GlobalData’s detailed insights on Myriad Genetics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.
